Efficacy
Median follow-up for rPFS was 17.5 and 16.8 months for the talazoparib and placebo groups, respectively. Talazoparib plus enzalutamide significantly improved rPFS by blinded independent central review compared with placebo plus enzalutamide (HR, 0.45; 95% CI, 0.33 to 0.61; 